Two human breast carcinoma cell lines, MDA-MB-468 and its variant MDA-MB-468LN, which displays aggressive lymphatic metastasis, were investigated for molecular cytogenetic characteristics using G-banding, spectral karyotyping, and fluorescence in situ hybridization (FISH). Both cell lines have multiple chromosome aberrations, but differ in the types of rearrangements and their breakpoints. The MDA-MB-468 karyotype identified in the present study differs from that previously reported, which suggests that this cell line is unstable. Neither cell line exhibited amplification of ERBB2 (alias HER-2) by FISH. MDA-MB-468 cells have a modal number of 60, with 42 types of aberrations: 11 numerical and 31 structural. 468LN cells have a modal number of 55, with 37 types of aberrations: 10 numerical and 27 structural. The most common aberrations in MDA-MB-468 cells were der(5)t(5;16), i(7)(p10), i(18)(p10), der(19)t(2;19), del(6)(q23), and der(10)t(1;10). The most common aberrations in 468LN cells were der(18)t(10;18), +5, der(1;7)(q10;q10), der(19)t(2;18;19), and der(20)t(20;21). This cytogenetic result is consistent with previous findings that showed differences in tumorigenicity and metastatic capability of these two cell lines and indicates that 468LN is a new cell line distinctive from MDA-MB-468. We hypothesize that the cytogenetic changes in 468LN may be related to its new biological characteristics. Knowledge of the chromosome aberrations and breakpoints identified could be useful for further genetic and epigenetic studies of breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cancergencyto.2007.05.030 | DOI Listing |
BMC Res Notes
December 2024
Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan.
Introduction: DU145 and LNCaP are classic prostate cancer cell lines. Characterizing their baseline transcriptomics profiles (without any intervention) can offer insights into baseline genetic features and oncogenic pathways that should be considered while interpreting findings after various experimental interventions such as exogenous gene transfection or drug treatment.
Methods: LNCaP and DU145 cell lines were cultured under normal conditions, followed by RNA extraction, cDNA conversion, library preparation, and RNA sequencing using the Illumina NovaSeq platform.
Clin Epigenetics
December 2024
Hereditary Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Background: Lynch syndrome (LS), characterised by an increased risk for cancer, is mainly caused by germline pathogenic variants affecting a mismatch repair gene (MLH1, MSH2, MSH6, PMS2). Occasionally, LS may be caused by constitutional MLH1 epimutation (CME) characterised by soma-wide methylation of one allele of the MLH1 promoter. Most of these are "primary" epimutations, arising de novo without any apparent underlying cis-genetic cause, and are reversible between generations.
View Article and Find Full Text PDFBreast Cancer Res
December 2024
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Background: Triple negative breast cancer (TNBC) belongs to the worst prognosis of breast cancer subtype probably because of distant metastasis to other organs, e.g. lungs.
View Article and Find Full Text PDFJ Transl Med
December 2024
Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Background: Gasdermin D (GSDMD) is a key effector molecule that activates pyroptosis through its N terminal domain (GSDMD-NT). However, the roles of GSDMD in colorectal cancer (CRC) have not been fully explored. The role of the full-length GSDMD (GSDMD-FL) is also not clear.
View Article and Find Full Text PDFJ Transl Med
December 2024
Gastroenterology Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324 JingwuWeiqi Road, Jinan, Shandong, 250021, China.
Background: The overall prognosis of patients with esophageal cancer (EC) is extremely poor. There is an urgent need to develop innovative therapeutic strategies. This study will investigate the anti-cancer effects of exosomes loaded with specific anti-cancer microRNAs in vivo and in vitro.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!